One could argue that CMS is restricting coverage of a particular instance of an accelerated approval and a set of potential approvals for a narrowly defined sub-class of beta amyloid-directed monoclonal antibodies. And this particular decision has no universal implications outside of this sub-class.
Subscribe to:
Post Comments (Atom)
< + > PerfectServe Uses AI to Transform Healthcare Workflow Orchestration
After 30 years of orchestrating workflows and connecting systems across providers and IT vendors, PerfectServe continues to expand what it ...
No comments:
Post a Comment